Brenda Diergaarde1, Michelle L Kurta. 1. aDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania bThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk. RECENT FINDINGS: Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain. In addition, it may currently just be too early to determine whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range. SUMMARY: Whether use of fertility drugs increases the risk of ovarian cancer is an important question that requires further investigation, in particular given the large number of women utilizing fertility treatments. Fortunately, results from recent studies have been mainly reassuring. Large well designed studies with sufficient follow-up time are needed to further evaluate the effects of fertility treatments within subgroups defined by patient and tumour characteristics.
PURPOSE OF REVIEW: The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk. RECENT FINDINGS: Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain. In addition, it may currently just be too early to determine whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range. SUMMARY: Whether use of fertility drugs increases the risk of ovarian cancer is an important question that requires further investigation, in particular given the large number of women utilizing fertility treatments. Fortunately, results from recent studies have been mainly reassuring. Large well designed studies with sufficient follow-up time are needed to further evaluate the effects of fertility treatments within subgroups defined by patient and tumour characteristics.
Authors: Maite Cusidó; Lorenzo Balagueró; Gines Hernandez; Orlando Falcón; Francisco José Rodríguez-Escudero; José Antonio Vargas; José Antonio Vidart; L Zamora; M Monera; Asunción Alonso Journal: Gynecol Oncol Date: 2006-11-16 Impact factor: 5.482
Authors: Kim N Danforth; Shelley S Tworoger; Jonathan L Hecht; Bernard A Rosner; Graham A Colditz; Susan E Hankinson Journal: Cancer Causes Control Date: 2007-04-21 Impact factor: 2.506
Authors: Shelley S Tworoger; Kathleen M Fairfield; Graham A Colditz; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2007-07-26 Impact factor: 4.897
Authors: Albert Asante; Phoebe H Leonard; Amy L Weaver; Ellen L Goode; Jani R Jensen; Elizabeth A Stewart; Charles C Coddington Journal: Fertil Steril Date: 2013-04-01 Impact factor: 7.329
Authors: Sevastiani Antonouli; Maria Grazia Palmerini; Serena Bianchi; Gianna Rossi; Sandra Cecconi; Manuel Belli; Sara Bernardi; Mohammad Ali Khalili; Giuseppe Familiari; Stefania Annarita Nottola; Guido Macchiarelli Journal: J Reprod Dev Date: 2020-04-28 Impact factor: 2.214
Authors: Arati Inamdar; Adriana Fulginiti; Shuk Fong Yiu; Abraham Loo; Brian Rogers; Robert Massaro; Robert A Graebe; Thomas E Hackett Journal: Case Rep Obstet Gynecol Date: 2020-01-03